论文部分内容阅读
目的观察细胞因子诱导的杀伤细胞(CIK细胞)对造血干细胞移植后血液肿瘤患者维持治疗的疗效。方法 2005年9月至2010年6月收治血液恶性肿瘤患者12例,其中行自体造血干细胞移植8例,异基因造血干细胞移植4例;移植造血重建后1~3个月内,利用血细胞分离机分离患者(自体移植)及供者(异体移植)的外周血单个核细胞,在体外用多种细胞因子[抗CD3单克隆抗体(OKT3)、白介素-2(IL-2)、干扰素-γ(IFN-γ)等)]共同培养后获得CIK细胞,分次回输给患者。随访观察患者接受治疗后血常规及骨髓等指标的变化及不良反应,同时记录患者的生存期。结果 8例自体干细胞移植患者有2例复发,其中1例17个月后死亡,其余6例长期生存;4例异体干细胞移植患者有1例复发,5个月后死亡,其余3例长期生存;4例患者静脉滴注CIK细胞时出现畏寒、寒战、发热,经对症处理均缓解,其余未见不良反应。结论造血干细胞移植后CIK细胞生物治疗延长了患者的生存期,改善了患者的生活状况,未见明显不良反应。
Objective To observe the effect of cytokine-induced killer (CIK) cells on the maintenance of hematologic malignancies after hematopoietic stem cell transplantation. Methods From September 2005 to June 2010, 12 patients with hematological malignancies were treated, including 8 cases of autologous hematopoietic stem cell transplantation and 4 cases of allogeneic hematopoietic stem cell transplantation. Within 1 to 3 months after transplantation, hematopoietic cells Peripheral blood mononuclear cells from patients (autograft) and donor (allograft) were isolated and purified in vitro using various cytokines (anti-CD3 monoclonal antibody (OKT3), interleukin-2 (IFN-γ), etc.)] were co-cultured to obtain CIK cells, graded back to the patient. Follow-up observation of patients after treatment of blood and bone marrow and other indicators of changes and adverse reactions, while recording the survival of patients. Results In 8 patients with autologous stem cell transplantation, 2 patients relapsed. One patient died after 17 months and the other 6 patients survived for a long time. One patient recurred in 4 patients after allogeneic stem cell transplantation and died after 5 months. The remaining 3 patients survived long - term. 4 cases of patients with CIK cells intravenous chills, chills, fever, the symptomatic treatment were relieved, the rest without adverse reactions. Conclusion Biological treatment of CIK cells after hematopoietic stem cell transplantation prolongs the survival of patients and improves the living conditions of patients without obvious adverse reactions.